LBA73SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

P Nathan, A Needham, P G Corrie, S Danson, J Evans, S Ochsenreither, S Kumar, A Goodman, J M G Larkin, I Karydis, N M Steven, P Lorigan, R Plummer, P Patel, H M Shaw, S Leyvraz, C Rawcliffe, E E Psarelli, L Handley, J J Sacco

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalAnnals of Oncology
Issue numberSupplement_5
Publication statusPublished - 1 Oct 2019

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Cite this